慢性阻塞性肺疾病患者家庭无创通气的成本效益分析
该研究采用Markov模型成本-效用分析,从英国国家卫生服务体系视角比较家庭无创通气与常规护理对两组终末期慢阻肺患者的成本效益。结果显示,在出院后人群中家庭无创通气具有99.9%的概率符合成本效益阈值,但在稳定期人群中仅4%概率符合,结论存在不确定性。
要点
- 出院后慢阻肺患者使用家庭无创通气极可能具有成本效益。
- 稳定期慢阻肺患者使用家庭无创通气的成本效益尚不确定。
- 成本效益估计对长期再入院和死亡风险及获益持续时间敏感。
核心结论
- 家庭无创通气对出院后慢阻肺患者可能具有成本效益,对稳定期患者的成本效益存在不确定性,需进一步研究。
研究设计与样本
- 基于Markov模型的成本-效用分析,从英国国家卫生服务体系视角比较家庭无创通气与常规护理,针对两组终末期慢阻肺人群:稳定期无近期住院患者和因急性加重住院后出院患者。
临床怎么用
- 对于因慢阻肺急性加重住院后的患者,可优先考虑家庭无创通气以改善成本效益。
- 对于稳定期慢阻肺患者,家庭无创通气的成本效益尚不明确,决策需结合个体风险。
局限性
- 住院率数据来源于随机对照研究的系统评价,其他模型参数基于近期证据更新,可能存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a chronic disease associated with recurring exacerbations, which influence morbidity and mortality for the patient, while placing significant resource burdens on healthcare systems. Non-invasive ventilation (NIV) in a domiciliary setting can help prevent admissions, but the economic evidence to support NIV use is limited. METHODS: A Markov model-based cost-utility analysis from the UK National Health Service perspective compared the cost-effectiveness of domiciliary NIV with usual care for two end-stage COPD populations; a stable COPD population commencing treatment with no recent hospital admission; and a posthospital population starting treatment following admission to hospital for an exacerbation. Hospitalisation rates in patients receiving domiciliary NIV compared with usual care were derived from randomised controlled studies in a recent systematic review. Other model parameters were updated with recent evidence. RESULTS: At the threshold of £20 000 per quality-adjusted life-year (QALY) domiciliary NIV is 99.9% likely cost-effective in a posthospital population, but unlikely (4%) to be cost-effective in stable populations. The incremental cost-effective ratio (ICER) was £11 318/QALY gained in the posthospital population and £27 380/QALY gained in the stable population. Cost-effectiveness estimates were sensitive to longer-term readmission and mortality risks, and duration of benefit from NIV. Indeed, for stable Global Initiative for Chronic Obstructive Lung Disease (GOLD) for stage 4 patients, or with higher mortality and exacerbation risks, ICERs were close to the £20 000/QALY threshold. CONCLUSION: Domiciliary NIV is likely cost-effective for posthospitalised patients, with uncertainty around the cost-effectiveness of domiciliary NIV in stable patients with COPD on which further research should focus.
引用
- Hall, Turner, Dretzke, et al. Cost-effectiveness of domiciliary non-invasive ventilation in patients with chronic obstructive pulmonary disease. Thorax. 2021. PMID: 34836922. doi:10.1136/thoraxjnl-2021-217463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。